Pular para o conteúdo
Merck
Todas as fotos(1)

Key Documents

E0504

Sigma-Aldrich

Ecarin from Echis carinatus venom

prothrombin activator

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Número CAS:
Número MDL:
Código UNSPSC:
12352202
NACRES:
NA.61

fonte biológica

Echis carinatus venom

Nível de qualidade

embalagem

vial of 45-55 units

temperatura de armazenamento

−20°C

Aplicação

Ecarin from Echis carinatus venom is the primary reagent in the ecarin clotting time (ECT) test, which is used to monitor anticoagulation and thrombin inhibition. It has been used in studies to test the effectiveness of medications for the treatment of venous and arterial thromboembolism.
Ecarin activity is the principal behind the Ecarin Clotting Time (ECT) assay, which is used to assess antithrombotic effect and thrombin inhibition.

Ações bioquímicas/fisiológicas

Prothrombin activator

Definição da unidade

One unit will activate prothrombin to produce one unit of amidolytic activity at pH 8.4 at 37 °C. One amidolytic unit will hydrolyze 1.0 μmole of N-p-tosyl-Gly-Pro-Arg-p-nitroanilide per min at pH 8.4 at 37 °C.

Pictogramas

Health hazard

Palavra indicadora

Danger

Frases de perigo

Declarações de precaução

Classificações de perigo

Resp. Sens. 1 - Skin Sens. 1

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Equipamento de proteção individual

dust mask type N95 (US), Eyeshields, Faceshields, Gloves


Certificados de análise (COA)

Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Elise S Eerenberg et al.
Circulation, 124(14), 1573-1579 (2011-09-09)
Rivaroxaban and dabigatran are new oral anticoagulants that specifically inhibit factor Xa and thrombin, respectively. Clinical studies on the prevention and treatment of venous and arterial thromboembolism show promising results. A major disadvantage of these anticoagulants is the absence of
Wei Zhou et al.
Stroke, 42(12), 3594-3599 (2011-10-15)
Dabigatran-etexilate (DE) recently has been approved for stroke prevention in atrial fibrillation. However, lack of effective antagonists represents a major concern in the event of intracerebral hemorrhage (ICH). The aims of the present study were to establish a murine model
Lambro A Johnson et al.
Analytical biochemistry, 608, 113907-113907 (2020-08-20)
Snake venom prothrombin activators such as Ecarin are readily assayed by continuous spectrophotometric monitoring of p-nitroaniline production in a one step assay containing prothrombin and a p-nitroanilide peptide substrate for thrombin. The coupled reactions result in accelerating p-nitroaniline (pNA) production
Kevin Dietrich et al.
Thrombosis research, 135(4), 630-635 (2015-02-27)
Age-related changes in the hemostatic system result in variation in response to anticoagulants and coagulation assays over childhood. This study used in vitro methods to determine i) optimum coagulation assays for dabigatran in children and ii) anticoagulant effect of dabigatran

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica